Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on October 31, 2019. The filing reports the appointment of a new executive officer and the terms of the associated employment agreement.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Yash Singh as Executive Vice President, Cellular and Molecular Technologies, effective October 31, 2019. Mr. Singh joins from Analogic Corporation, where he served as President of Power and Robotics Motion since 2009.
Guidance, Outlook, and Compensation Details
The filing details the terms of Mr. Singh's employment agreement, which includes the following compensation components:
- Base Salary: $320,000 annually.
- Cash Incentive: Eligible for up to 50% of base salary commencing in fiscal year 2020, subject to meeting objectives.
- Stock Options: Grant of 86,614 options with an exercise price of $2.80, vesting in four equal annual installments.
- Restricted Stock Units (RSUs): Market condition deferred stock award with a target of 39,286 shares. Vesting is based on relative total shareholder return compared to the NASDAQ Biotechnology index. The maximum award is 150% of the target; awards below the 20th percentile are forfeited.
- Severance and Change-in-Control: The agreement includes provisions for payments upon termination without cause, for good reason, death, disability, or change-in-control, including acceleration of vesting and severance benefits.
The agreement term is one year with automatic one-year extensions unless terminated with 90 days' notice.
Investor Verification Checklist
- Verify the impact of the new executive leadership on the Cellular and Molecular Technologies segment.
- Review the full Employment Agreement (Exhibit 10.1) for specific definitions of "cause," "good reason," and change-in-control triggers.
- Monitor the vesting schedule and performance metrics for the market condition RSUs relative to the NASDAQ Biotechnology index.
- Check subsequent filings for any changes to the company's financial outlook resulting from this leadership change.